Breaking News, Financial News

Financial Report: Roche

Pharmaceuticals Division sales were up 11% for the year

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche FY Revenues: 61.5 billion CHF (+8%) FY Earnings: 14.1 billion CHF (+30%) Comments: Pharmaceuticals Division sales were up 11% to CHF 48.5 billion, driven by recently launched products led by multiple sclerosis medicine Ocrevus, the new haemophilia medicine, Hemlibra and cancer medicines Tecentriq and Perjeta, offsetting the impact of competition from biosimilars for MabThera/Rituxan and Herceptin in Europe and Japan (decline combined CHF 1.2 billion) and MabThera/Rituxan, Herce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters